NEU

0.81%

$12.25 neuren pharmaceuticals limited

You always provide such insight. I tend to speak in general...

First 9 Last

Share
Profile

Follow
Innameonly

162 Posts.

180

21/08/24

12:32

Post #: 75303345
Share

Originally posted by hottod: ↑

Neuren seems to be most similar to Cerevel and Prometheus Biosciences, rather than Reata, who had a drug already approved…. I genuinely believe Neuren will be competed for as Prometheus Biosciences was.

Innameonly, I’m not in agreement with you on this. Apples and oranges.

Yes, Merck acquired the clinical-stage biotech Prometheus for US$10.8bn following “encouraging” mid-phase results. And yes, that demonstrates that pharma doesn’t always wait for Phase 3 proof and/or FDA approval before pouncing on coveted assets.

But this is not just about the stage that the company is at, it’s also about considerations such as therapeutic areas and patient populations sizes.

Prometheus specialized in antibody treatments for autoimmune diseases.

Immunology is one of the “hot” areas for pharma, along with diabetes and obesity drugs and the always-popular area of oncology. These are the therapeutic areas anticipated to be the biggest contributors to pharma revenue growth in the near future. Consequently, all of the larger pharma are keen to have a strong presence in these areas. As the Merck CEO said, "I believe now we have a very strong portfolio in the cardiometabolic space. We see this acquisition of Prometheus building out a similar portfolio in the immunology space."

The main targeted molecule in this deal was being developed in ulcerative colitis and Crohn’s disease. Approximately 1 million Americans have a diagnosis of ulcerative colitis and approximately 750,000 have Crohn’s disease. For the broader area of inflammatory bowel disease (IBD) there are over 7 million sufferers globally.

Prometheus also had a discovery engine platform for novel precision therapeutics and diagnostics, which included a clinical database and associated biobank with one of the world’s largest collections of biospecimens from patients suffering from IBD and other GI disorders. That would be of significant interest and value to pharma.

Neuren’s current portfolio of small molecule, rare, neurodevelopmental disease assets is more niche. This is not to say that I doubt that pharma will be interested, I believe they will – it’s just that I think that there are likely to be fewer pharma suitors for such assets and these will most likely be those with an already-established presence in rare disease and neurology.

Expand

You always provide such insight.

I tend to speak in general terms and don't have your knowledge. I was making the comparison more on the stage of progress and hoping the high cost of 2591 goes a long way to making up for the niche aspect. How do you feel about the Reata comparison?

NEU Price at posting: $15.23 Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

MIN

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

DXB

Dimerix links up with US NEPTUNE network to boost recruitment for FSGS study

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Making money: How many microcaps should be in an investor's portfolio?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

There are more pages in this discussion • 115 more messages in this thread...

First 9 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $12.25		Change -0.100(0.81%)		Mkt cap ! $1.565B

Open	High	Low	Value	Volume
$12.20	$12.25	$12.02	$3.677M	302.0K

Buyers (Bids)

No.	Vol.	Price($)
1	1579	$12.21

Sellers (Offers)

Price($)	Vol.	No.
$12.26	1199	1

View Market Depth

No.	Vol.	Price($)
1	1579	12.210
1	3813	12.170
1	1199	12.160
4	3337	12.150
1	1199	12.140

Price($)	Vol.	No.
12.260	1199	1
12.270	1078	2
12.280	1199	1
12.300	1199	1
12.310	1199	1

Last trade - 16.10pm 01/11/2024 (20 minute delay)

NEU (ASX) Chart

You always provide such insight. I tend to speak in general...

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

Dimerix links up with US NEPTUNE network to boost recruitment for FSGS study

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Making money: How many microcaps should be in an investor's portfolio?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

You always provide such insight. I tend to speak in general...

Top Stories

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

Dimerix links up with US NEPTUNE network to boost recruitment for FSGS study

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Making money: How many microcaps should be in an investor's portfolio?

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News